Stock values continued to soar all last week for IntraBiotics Pharmaceuticals Inc. on two news items related to its lead product, iseganan hydrochloride, the latest of which outlined a special protocol assessment agreement with the FDA. (BioWorld Today)

IntraBiotics Receives FDA Nod To Proceed With Pivotal Trials

Sep. 22, 2003

By Aaron Lorenzo

No Comments

Today's news in brief
BioWorld
BioWorld briefs for Jan. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 24, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Abbvie and Simcere enter a $1B T-cell engager deal
BioWorld Asia
Abbvie Inc. and Simcere Zaiming Pharmaceutical Co. Ltd. are part of the volley of large deals accompanying the opening of the 43rd annual J.P. Morgan Healthcare...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.